New York State Common Retirement Fund Trims Stake in Renovaro Inc. (NASDAQ:RENB)

New York State Common Retirement Fund reduced its holdings in shares of Renovaro Inc. (NASDAQ:RENB) by 21.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 52,500 shares of the company’s stock after selling 14,200 shares during the period. New York State Common Retirement Fund’s holdings in Renovaro were worth $44,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC increased its stake in shares of Renovaro by 193.3% in the fourth quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock worth $43,000 after purchasing an additional 34,090 shares in the last quarter. Barclays PLC increased its stake in shares of Renovaro by 315.7% in the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after purchasing an additional 52,804 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Renovaro by 347.6% during the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock valued at $45,000 after acquiring an additional 72,230 shares in the last quarter. Rhumbline Advisers grew its stake in Renovaro by 122.6% during the fourth quarter. Rhumbline Advisers now owns 112,960 shares of the company’s stock valued at $94,000 after acquiring an additional 62,204 shares in the last quarter. Finally, State Street Corp grew its stake in Renovaro by 3.8% during the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after acquiring an additional 48,114 shares in the last quarter. 71.41% of the stock is owned by hedge funds and other institutional investors.

Renovaro Stock Performance

RENB opened at $0.84 on Friday. The stock has a market capitalization of $133.96 million, a price-to-earnings ratio of -0.91 and a beta of 0.63. The company has a fifty day moving average of $0.83 and a 200 day moving average of $0.78. Renovaro Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $3.38.

Renovaro (NASDAQ:RENB) last posted its earnings results on Wednesday, February 19th. The company reported ($0.02) earnings per share for the quarter.

Renovaro Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.